Say goodbye to masks or MADs – Say hello to daytime therapy.

eXciteOSA® for sleep apnea delivers NMES therapy and has been clinically proven to reduce sleep apnea. Use for just 20 minutes a day, every day for six weeks, to improve the quality of your sleep.1-3

Clinically proven daytime therapy. Nothing to wear at night.

Find out if you’re a candidate.

Take our two-minute assessment to start your journey towards a better night’s sleep.

Treatments

There are several options for treating mild obstructive sleep apnea

Many OSA therapies focus on creating space in the airway. NMES does something unique.

1. Nighttime treatments

Uncomfortable. Difficult to tolerate

Nighttime Therapy & CPAP for Snoring & For Sleep Apnea Device Diagram
MAD / CPAP

Mandibular (jaw) Advancement Devices work by temporarily moving the jaw forward. CPAP machines pump air pressure into your upper airway.

2. Surgical treatments

Invasive

Surgery

Surgery is usually an option after other treatments have failed. Examples include tissue or tonsil removal.

3. Daytime NMES therapy

Simple, effective & painless

daytime nmes therapy for better sleep
NMES

NMES physiologically retrains the upper airway and tongue, to stay in its natural position while you sleep.

eXciteOSA For Sleep Apnea – A Daytime Therapy

Neuromuscular electrical stimulation (NMES) with eXciteOSA®

NMES safely activates nerves and trains muscles. NMES is a familiar and well-established technique in medicine and athletics.

Sleep apnea has multiple causes, including reduced responsiveness of the tongue and upper airway muscles4.

eXciteOSA for sleep apnea changes this. It trains your tongue to stay in position, letting you sleep soundly.

NMES (eXciteOSA®)
NMES
MAD / CPAP
surgery
SURGERY
Treats a root cause of snoring
Nothing to wear at night
Evidence based
Low cost trial period
Helps your body to help itself

NMES is different

Convenient daytime therapy

Comfortable and painless leaving you with nothing to wear at night.

Reduces Apneas

A recent study found a 52% reduction in the AHI and a 50% reduction in the ODI amongst responders – all without a CPAP or MAD3.

Retrains the upper airway

Physiologically retrains the upper airway. No other device currently on the market does that.

The App

You are in control

Use the app to control the intensity of the stimulation and get guidance, reminders and notifications about your therapy.

Better sleep or your money back.*

If you do not experience improved sleep after completing 70% of 42 therapies in 8 weeks, we will refund you the price of the device.

Hear how eXciteOSA® has transformed people’s sleep

“I have this simple device… [that] I use during the day [so] that I can sleep quite happily without thinking about having to wear a mask at night.”

Local eXciteOSA Physician Sleep Specialists

Schedule a consultation now and start the discussion.

Find a Therapy That Works for You

OSA is a progressive disease that should be treated5-8

With new alternatives available, like daytime therapy, there is now no excuse. Consult a physician as, if left untreated, OSA places extra strain on your health.

224%
Patients with mild OSA have a 224% increased risk of developing hypertension compared to those without OSA9
83%
Patients with mild OSA are 83% more likely to be diagnosed with diabetes than those without OSA10
137%
OSA increases the risk of developing cognitive decline and Alzheimer’s disease by 137%11

Daytime therapy. No nighttime wearable.

Clinically proven to reduce mild OSA in just 6 weeks

Trusted by Experts

Backed by leading sleep specialists

“I have been positively encouraged and impressed with the early results in patients with snoring and mild sleep apnoea.”

— Professor Bhik Kotecha

  • Consultant Ear, Nose & Throat Surgeon
  • Nuffield Health Brentwood Hospital, London, UK

“Patients wish there was an alternative non-invasive solution that was not used nocturnally. I am very excited to finally offer them this solution.”

— Dr. Scott Skibo, MD, FCCP

  • Pulmonologist
  • Haywood Regional Medical Center, NC, USA

“We believe that eXciteOSA therapy will be able to help many patients in the near future.”

— Dr. Marina Carrasco-Llatas

  • Specialist in ORL at Dr. Peset University Hospital, Valencia, Spain
  • Expert in Sleep Medicine
  • President of the Commission on Roncopathy and Sleep Apnoea of the Spanish Society of Otolaryngology and Head and Neck Surgery

“I am optimistic that this treatment will be an important treatment approach for patients with with mild sleep apnea and snoring.”

— Professor Atul Malhotra

  • M.D. Research Chief, Pulmonary, Critical Care and Sleep Medicine
  • Peter C. Farrell Presidential Chair and Professor in Respiratory Medicine
  • Former President, American Thoracic Society 2015- 2016

“What is truly revolutionary is that this device actually trains the muscles that go slack and cause snoring.”

— Dr. Gurs Sehmi

  • Sleep Dentist
  • London, UK

“This device is unique as it is worn briefly during the day and thus no interference with sleep. There is no other product on the market like eXciteOSA®.”

— Tanya A Wiese, DO

  • Pulmonologist
  • Norton Pulmonary Specialists, KY, USA

“A new treatment I feel enthusiastic about is eXciteOSA®. I have recommended patients who snore or have mild sleep apnoea to try it.”

— Adrian Williams, FRCP, FAASM

  • Consultant in Sleep Medicine
  • Professor of Sleep Medicine

Frequently asked questions

Transcutaneous electrical nerve stimulation (TENS) machines stimulates the sensory nerves (the nerves that send signals from the body to the brain) with the purpose of disrupting the pain signal.

Neuromuscular electrical stimulation (NMES) also uses electrical stimulation, but targets the motor nerves (the nerves that send signals from the brain to the body) in order to stimulate the muscles directly.

Sensory and motor nerves fire at different frequencies, which is how TENS and NMES devices are able to impact them differently.

eXciteOSA® is a user-controllable neuromuscular electrical stimulator (NMES) that delivers a mild electrical current with defined frequencies to stimulate and improve muscle function in the mouth and tongue.

Unlike traditional sleep apnea treatments, eXciteOSA® targets the tongue to promote endurance of the muscle, thereby reducing airway collapse and snoring during sleep.

A daytime therapy with no night-time wearable necessary for a better night’s sleep.

There are several options for treating sleep apnea.

Manudibular advancement devices (MADs) work by temporarily moving the jaw forward, in order to create more space in the airway.

CPAP delivers air pressure through a mask to open up the airway.

Surgery is usually an option to consider after other treatments have failed. Examples include removal of soft tissues from the airway, or procedures designed to stiffen the airway.

NMES physiologically retrains the upper airway and tongue to maintain the tongue’s natural position while you sleep, effectively helping your body help itself. eXciteOSA For Sleep Apnea is the only device that delivers NMES. You can also refer to the chart above to better illustrate the main difference.

Risk-free trial

*The eXciteOSA Better Sleep Guarantee: Consistent use is critical to success. While we don’t expect perfection, we do ask that you complete 70% of your 42 therapies within 8 weeks of receiving your product before receiving your refund. Refunds are available to customers who purchased eXciteOSA without using covered benefits or had the device reimbursed under any type of health insurance.

A session is equivalent to 20 minutes. In addition, it is recommended that you increase the therapy intensity gradually over the treatment period to ensure that you give the treatment every chance of being effective. Please note that once the initial therapy is finished and to maintain the treatment you need to use the device at least twice a week forever.

The mouthpiece is a precision piece of engineering responsible for delivering neuromuscular electrical stimulation targeted primarily at the tongue. It needs to be replaced every 3 months.

References

  1. Kotecha B, Wong PY, Zhang H, Hassaan A. A novel intraoral neuromuscular stimulation device for treating sleep-disordered breathing. Sleep Breath 2021;25(4):2083-2090.
  2. Baptista PM, Martinez Ruiz de Apodaca P, Carrasco M, Fernandez S, Wong PY, Zhang H, Hassaan A, Kotecha B. Daytime neuromuscular electrical therapy of tongue muscles in improving snoring in individuals with primary snoring and mild obstructive sleep apnea. J Clin Med 2021;10(9):1-11.
  3. Nokes B, Baptista PM, Martínez Ruiz de Apodaca P, Carrasco-Llatas M, Fernandez S, Kotecha B, Wong PY, Zhang H, Hassaan A, Malhotra A. Transoral awake state neuromuscular therapy for mild obstructive sleep apnea. Sleep Breath [accepted; in-press].
  4. Eckert DJ, White DP, Jordan AS, Malhotra A, Wellman A. Defining phenotypic causes of obstructive sleep apnea: Identification of novel therapeutic targets. Am J Respir Crit Care Med 2013;188(8):996-1004.
  5. Peppard PE, Young T, Palta M, Dempsey J, Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. JAMA 2000;284:3015-3021.
  6. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002;165:1217-1239.
  7. Newman AB, Foster G, Givelber R, Nieto FJ, Redline S, Young T. Progression and regression of sleep-disordered breathing with changes in weight: the Sleep Heart Health Study. Arch Intern Med 2005;165:2408-2413.
  8. Redline S, Schluchter MD, Larkin EK, Tishler PV. Predictors of longitudinal change in sleep-disordered breathing in a nonclinic population. Sleep 2003;26:703-709.
  9. Vgontzas AN, Li Y, He F, Fernandez-Mendoza J, Gaines J, Liao D, Basta M, Bixler EO. Mild-to-moderate sleep apnea is associated with incident hypertension: age effect. Sleep 2019;42(4):zsy265.
  10. Reichmuth KJ, Austin D, Skatrud JB, Young T. Association of sleep apnea and type II diabetes: a population-based study. Am J Respir Crit Care Med 2005;172(12):1590-1595.
  11. Bubu OM, Brannick M, Mortimer J, Umasabor-Bubu O, Sebastiao YV, Wen Y, Schwartz S, Borenstein AR, Wu Y, Morgan D, Anderson WM. Sleep, Cognitive impairment, and Alzheimer’s disease: A Systematic Review and Meta-Analysis. Sleep 2017;40(1):zsw032.